ArticleBMC cancer2025

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.

Junya Furukawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.